• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    INmune Bio Inc. - Common stock (NQ:INMB)

    1.900 -0.050 (-2.56%)
    Delayed Quote Updated: 11:20 AM EDT, Oct 1, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about INmune Bio Inc. - Common stock

    < Previous 1 2 3 4 5 6 7 8 9 Next >
    News headline image
    INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the Offering
    From INmune Bio, Inc.
    Via GlobeNewswire
    News headline image
    INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024
    From INmune Bio, Inc.
    Via GlobeNewswire
    News headline image
    INmune Bio: Q4 Earnings Insights ↗
     
    Via Benzinga
    News headline image
    A Preview Of INmune Bio's Earnings ↗
     
    Via Benzinga
    News headline image
    Earnings Outlook For INmune Bio ↗
     
    Via Benzinga
    News headline image
    INMB Stock Earnings: INmune Bio Misses EPS, Misses Revenue for Q4 2023 ↗
    INMB stock results show that INmune Bio missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023. 
    Via InvestorPlace
    News headline image
    Earnings Scheduled For March 28, 2024 ↗
    Companies Reporting Before The Bell • Universal Stainless (NASDAQ:USAP) is expected to report quarterly earnings at $0.32 per share on revenue of $78.65 million. 
    Via Benzinga
    News headline image
    INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28
    From INmune Bio, Inc.
    Via GlobeNewswire
    News headline image
    INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene Therapy
    From INmune Bio, Inc.
    Via GlobeNewswire
    News headline image
    INmune Bio Reports Significant EEG Improvement in Alzheimer’s Patients Treated with XPro™
    From INmune Bio, Inc.
    Via GlobeNewswire
    News headline image
    INmune Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
    From INmune Bio, Inc.
    Via GlobeNewswire
    News headline image
    INmune Bio to Participate in Baird’s Biotech Discovery Series Webcast on February 13, 2024
    From INmune Bio, Inc.
    Via GlobeNewswire
    News headline image
    INmune Bio Announces FDA Removal of Clinical Hold for Alzheimer’s Disease Program
    From INmune Bio, Inc.
    Via GlobeNewswire
    News headline image
    Why Is Elevai Labs (ELAB) Stock Up Today? ↗
    Elevai Labs is soaring on an intriguing licensing agreement with INmune Bio, but the narrative presents a mixed bag for ELAB stock. 
    Via InvestorPlace
    News headline image
    Why Elevai Labs Stock Is Trading Higher ↗
    Elevai Labs, Inc. (NASDAQ:ELAB) shares are trading higher Tuesday after the company announced it signed an exclusive, worldwide manufacturing and processing technology licensing agreement with INmune... 
    Via Benzinga
    News headline image
    ELEVAI Labs, Inc. Acquires Worldwide License Agreement for Proprietary Stem Cell Manufacturing Technology
    ELEVAI Labs to commercialize use of proprietary technology designed to produce high-quality, cGMP grade mesenchymal stromal cells at lower-cost 
    From Elevai Labs Inc.
    Via GlobeNewswire
    News headline image
    INmune Bio Announces First Patient Dosed in a Phase 1/2 Study of INKmune™ in Patients with Metastatic Castration-Resistant Prostate Cancer
    From INmune Bio, Inc.
    Via GlobeNewswire
    News headline image
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗
    It's time to dive into the biggest pre-market stock movers as we check out all of the most recent news for Tuesday morning! 
    Via InvestorPlace
    News headline image
    INmune Bio Provides Update Regarding Global Alzheimer’s Phase II Clinical Trial and Clinical Hold Issued by the United States FDA
    From INmune Bio, Inc.
    Via GlobeNewswire
    News headline image
    INmune Bio Inc. Demonstrates that INB03 Enhances the Uptake of Trastuzumab Deruxtecan in HER2+ Breast Cancer with MUC4 Expression in Poster Presented at San Antonio Breast Cancer Symposium
    From INmune Bio, Inc.
    Via GlobeNewswire
    News headline image
    INmune Bio Receives EMA’s Authorization in France and Spain for Phase II Clinical Trial of XPro™ for Early Alzheimer’s Disease
    From INmune Bio, Inc.
    Via GlobeNewswire
    News headline image
    Quest For Alzheimer's Cure: Big Biotech Breakthroughs, But The Race Is Just Beginning ↗
    Biotech companies are edging closer to finding the answers behind Alzheimer's disease. 
    Via Investor's Business Daily
    News headline image
    INmune Bio Inc. Announces Expansion of Phase II Clinical Trial for Alzheimer’s Disease in Europe
    The Company received regulatory approval to extend its Phase II trial of XPro™ in individuals with early Alzheimer’s disease in Poland, with additional European Union (EU) countries expected to open... 
    From INmune Bio, Inc.
    Via GlobeNewswire
    News headline image
    INmune Bio Inc. Patent Claims Covering INB16 Cell Line and INKmune™ Therapeutic Composition given Favorable Patentability Opinion by International Search Authority
    From INmune Bio, Inc.
    Via GlobeNewswire
    News headline image
    INmune Bio Inc. Presents Preclinical Data at SITC 2023 Showing INB03 is an Innate Immune Check Point Inhibitor that Downregulates SIRPα
    From INmune Bio, Inc.
    Via GlobeNewswire
    News headline image
    INmune Bio Inc. Presents New Biomarker and Feasibility Data from Phase 1b Study Supporting the Use of XPro™ to Treat Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease (CTAD) Conference
    From INmune Bio, Inc.
    Via GlobeNewswire
    News headline image
    INmune Bio Inc. to Report Third Quarter 2023 Financial Results and Provide a Corporate Update on Wednesday, November 1
    From INmune Bio, Inc.
    Via GlobeNewswire
    News headline image
    INmune Bio Inc. to Present at Baird Global Healthcare Conference and H.C Wainwright 25th Annual Global Investment Conference
    From INmune Bio, Inc.
    Via GlobeNewswire
    News headline image
    INmune Bio Inc. Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Phase 2 Clinical Trial in Alzheimer’s Disease
    From INmune Bio, Inc.
    Via GlobeNewswire
    News headline image
    INmune Bio Inc. to Present at the BTIG Virtual Biotechnology Conference
    From INmune Bio, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.